14-15 GLP-1 - Health space odyssey

For much of modern medicine, healthcare systems have been structured around treating disease once it becomes clinically apparent.

We screen for elevated blood glucose before diagnosing diabetes and we treat the consequences of cardiovascular disease once risk has translated into pathology.
While preventive medicine has always existed, it has historically been difficult to intervene earlier in the disease trajectory in a meaningful way. That may now be changing.

At the centre of this shift is a class of medications that many still dismiss as little more than ‘diet drugs’: GLP-1s.

Weight loss is the most visible outcome of GLP-1 medications. As the evidence base expands, it is becoming clear that their potential extends far beyond weight loss.

These medicines influence many of the metabolic pathways that underpin cardiometabolic disease. Emerging evidence suggests benefits across a range of conditions including cardiovascular disease and liver disease.

They represent more than a treatment for obesity. They offer the possibility of intervening earlier in the disease pathway, helping to reduce downstream complications and shifting healthcare systems from managing illness to preserving health.

GLP-1s could genuinely help shift our focus from extending lifespans to meaningfully expanding ‘healthspans’, the years we live in good, functional health.

To understand why a medication licensed for obesity may influence outcomes across multiple organ systems, it helps to look at the biology of cardiometabolic disease.

Obesity and type 2 diabetes are not isolated conditions. They are associated with complex metabolic dysregulation and a state of chronic low-grade inflammation that can affect tissues throughout the body.

When the body’s metabolic regulatory systems are persistently overloaded, inflammatory signalling can contribute to damage across several organs.

GLP-1 agonists appear to intervene in several points along this pathway. By mimicking a natural hormone produced in the gut, these medications influence appetite, insulin secretion, gastric emptying and glucose regulation.

In doing so, they improve overall metabolic control.

This broader metabolic effect may help explain why many patients report improvement beyond weight loss alone, including reduced joint pain and improved physical function.

While weight reduction plays an important role, the metabolic changes associated with GLP-1 therapy may also contribute to these wider benefits.

The strongest evidence for the preventative power of GLP-1s lies in cardiovascular health.

In adults with obesity and established cardiovascular disease, but without diabetes, semaglutide reduced the risk of major adverse cardiovascular events including heart attack and stroke by 20 percent compared with placebo.

Importantly, these reductions emerged relatively early in treatment, suggesting a direct cardioprotective mechanism that operates independently of weight loss.
Improvements in glycaemic control, blood pressure, lipid profiles and inflammatory signalling are all thought to contribute to this effect.

In the UK, this has already led to semaglutide becoming the first anti-obesity medication approved specifically to reduce the risk of future cardiac events in those with established cardiovascular disease.

We are no longer simply treating a number on a scale. We are actively modifying the trajectory of cardiometabolic disease.

The preventative potential of GLP-1s also extends to organs that sustain long-term damage from metabolic disease.

Chronic kidney disease often progresses silently for years before patients face the prospect of dialysis or transplantation.

Clinical trials have shown that once-weekly semaglutide can reduce the risk of major kidney complications by approximately 24% in patients with type 2 diabetes and chronic kidney disease.

These benefits are thought to arise from improved glycaemic control, reductions in blood pressure and body weight, and favourable effects on renal haemodynamic and inflammation.

The emerging picture in liver disease is equally compelling. In a 48-week trial, 39% of patients taking liraglutide saw their liver disease improve compared with 9% on placebo.

Clinical research with semaglutide has demonstrated even higher rates of disease resolution, with around 63% of participants experiencing improvements in fatty liver disease without worsening fibrosis and around 37% seeing improvements in fibrosis itself.

While weight loss and improved insulin sensitivity play a major role, GLP-1 therapies may also exert direct metabolic and anti-inflammatory effects within the liver.
Together, these findings suggest that treatment originally developed for diabetes and obesity may have a meaningful role in altering the long-term course of metabolic liver disease.

Perhaps the most intriguing area of emerging research is the potential impact of GLP-1s on neurological and respiratory health.

Observational studies using real-world data suggest a lower incidence of dementia, Parkinson’s disease and stroke among patients treated with GLP-1 medications compared with those receiving other diabetes therapies.

While these findings are preliminary, they have generated significant interest and research is underway to explore whether GLP-1 therapies may influence the biology of neurodegenerative disease.

Early signals are also emerging in respiratory disease. Retrospective analyses in patients with type 2 diabetes and asthma suggest that those prescribed GLP-1 medications experienced fewer exacerbations and improved disease control compared with those on other diabetes treatments.

Studies in patients with chronic obstructive pulmonary disease and type 2 diabetes point in the same direction.

The potential immune benefits became particularly visible during the COVID-19 pandemic. Data indicates that patients taking GLP-1 medications had lower mortality from serious infection.

Whilst causal mechanisms remain uncertain, these findings have further fuelled interest in the broader immunometabolism effects of this drug class.

The emerging evidence of GLP-1s extends into oncology.

Large observational analyses have reported that patients prescribed GLP-1s have a 17 percent lower incidence of certain cancers compared with those receiving other diabetes treatments.

The most significant reductions were seen in obesity-related malignancies such as endometrial and ovarian cancers.

By regulating insulin levels and reducing inflammation driven by excess adiposity, GLP-1s appear to remove the metabolic fuel that many tumours rely on to grow.

While these findings require confirmation in prospective research, they illustrate how therapies originally developed for diabetes and obesity may influence a broader spectrum of disease.

The emerging evidence suggests that the utility of GLP-1s extends far beyond obesity treatment.

What is becoming visible is the outline of a multisystem metabolic therapy with the potential to influence several of the chronic diseases that place the greatest burden on modern healthcare systems.

Realising that potential will require a shift in collective mindset.

If we continue to view these medications through the narrow lens of ‘diet drugs’, we risk overlooking their broader role in modifying cardiometabolic risk and preventing downstream complications such as heart failure, kidney disease and metabolic liver disease.

The challenge for the healthcare system is therefore not simply access to treatment but integration.

GLP-1 therapies will likely deliver their greatest value when used as part of a wider preventative strategy that combines medical treatment with lifestyle intervention, early risk identification and long-term patient engagement.

As clinicians, our goal is not only to extend life but to preserve the years lived in good health.

If the trajectory of current research continues, GLP-1 therapies may become one of the most important tools we have for shifting healthcare from the management of disease to the preservation of health.

Health space odyssey

Metabolic overflow

The heart shield

Protecting the body’s filters

Beyond metabolism

Cancer risk and oncological dimension

New model of wellness care